Related Experiment Video
Updated: May 22, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011
M R Jordan1, D E Bennett, M A Wainberg
1World Health Organization, Geneva, Switzerland. jordanm@who.int
Abstract:
The HIV drug resistance (HIVDR) prevention and assessment strategy, developed by the World Health Organization (WHO) in partnership with HIVResNet, includes monitoring of HIVDR early warning indicators, surveys to assess acquired and transmitted HIVDR, and development of an accredited HIVDR genotyping laboratory network to support survey implementation in resource-limited settings. As of June 2011, 52 countries had implemented at least 1 element of the strategy, and 27 laboratories had been accredited. As access to antiretrovirals expands under the WHO/Joint United Nations Programme on HIV/AIDS Treatment 2.0 initiative, it is essential to strengthen HIVDR surveillance efforts in the face of increasing concern about HIVDR emergence and transmission.
Related Concept Videos
Retrovirus Life Cycles
Therapeutic Drug Monitoring: Affecting Factors
Sexually Transmitted Infections
International Nursing Organizations II
The WHO provides expert team support, including funding, vaccines, testing, and treatment tools at the country level to fight...
Treatment Resistant Cancers
Therapeutic Drug Monitoring: Overview and Classification

